top of page
The Professional Network for Healthcare Experts
Fresenius and WuXi Biologics agree development partnership covering up to 37 biosimilar candidates
Fresenius has entered an exclusive development agreement with WuXi Biologics covering options for up to 37 biosimilar candidates, potentially more than doubling its combined marketed and pipeline portfolio.
nuaxia
2 days ago2 min read
Adalvo acquires Enzene romiplostim biosimilar programme targeting global Nplate market
Adalvo has acquired Enzene's romiplostim biosimilar programme, expanding its complex biologics portfolio with a candidate referencing Nplate for immune thrombocytopenia.
nuaxia
Oct 282 min read
bottom of page